Elke Boettcher

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Philip J. Mease, Désirée van der Heijde, Robert Landewé et al. · Annals of the Rheumatic Diseases · 2018 · 301 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

Désirée van der Heijde, Philip J. Mease, Robert Landewé et al. · Lara D. Veeken · 2019 · 55 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

Philip J. Mease, Robert Landewé, Proton Rahman et al. · RMD Open · 2021 · 41 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +12